Atlas Trials

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

Clinical trial NCT05206357 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05206357
Sponsor
Genmab
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Non-hodgkin Lymphoma
Start date
2022-10-04
Primary completion
2028-11-01
Enrollment
17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.